Glenmark Pharmaceuticals Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on Livemint - May 03, 2018 "Glenmark gets notice over misconduct in clinical trials".Glenmark Pharmaceuticals Ltd response is enclosed. Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on Livemint - May 03, 2018 titled "Glenmark gets notice over misconduct in clinical trials". The reply is awaited.
Glenmark gets notice over misconduct in clinical trials
The alleged misconduct on the part of Glenmark has triggered a tough response from apex drug regulatory body Glenmark Pharma gets USFDA nod for scalp and skin treatment drug
The company's current portfolio consists of 133 products authorised for distribution at the US marketplace and 60 abbreviated new drug applications pending approval with the USFDA Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Topical Solution USP, 0.05% Shareholding for the Period Ended March 31, 2018
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here Glenmark gets USFDA nod for skin ointment
Glenmark Pharmaceuticals has received final approval from the US health regulator for Tacrolimus ointment used for treating atopic dermatitis (eczem Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Ointment, 0.1% Glenmark Pharma initiates phase 2b clinical trial of atopic dermatitis drug
Glenmark Pharmaceuticals has initiated phase 2b clinical trial of GBR 830, a novel investigational treatment for moderate-to-severe atopic dermatitis Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub:- Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis